Despite the economic downturn, UK life sciences companies raised a healthy £382 million ($486 million) in new financing in the second quarter of the year, with venture cap
The UK government has formally opened a state-of-the-art vaccine research facility based at the UK Health and Security Agency (UKHSA) to improve the country's preparedness
Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disord
Plans for a major life sciences development at Canary Wharf in London, UK, have been approved by the local authorities, allowing the project to go ahead.
To meet its aspiration of becoming a life sciences superpower, the UK must not only discover and develop new medicines – it must also be able to manufacture them at scale,
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho